By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...
The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...
Vaccine maker's critics hope for new attorney general to reverse Pam Bondi's hostility to clinical trial whistleblower's ...
Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...
Pfizer (PFE) stock and BioNTech (BNTX) stock are in focus as a large U.S. trial for the companies' updated COVID-19 vaccine ...
The move comes as COVID vaccine makers grapple with pushback from the U.S. administration and weak U.S. demand for the ...
Pfizer Inc. (NYSE:PFE) is included among the 15 Cheapest Stocks with Highest Dividends. On April 1, Reuters reported that a ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
Pfizer and BioNTech have stopped their large U.S. COVID-19 vaccine trial in adults aged 50 to 64, citing insufficient ...
The Trump administration has also pushed back against Covid vaccine recommendations, and the FDA toughened its requirements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results